WO2015131176A1 - Compositions, procédés et trousses pour le traitement du cancer - Google Patents
Compositions, procédés et trousses pour le traitement du cancer Download PDFInfo
- Publication number
- WO2015131176A1 WO2015131176A1 PCT/US2015/018265 US2015018265W WO2015131176A1 WO 2015131176 A1 WO2015131176 A1 WO 2015131176A1 US 2015018265 W US2015018265 W US 2015018265W WO 2015131176 A1 WO2015131176 A1 WO 2015131176A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- cell
- host cells
- composition
- ligand
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 201000011510 cancer Diseases 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000011282 treatment Methods 0.000 title claims abstract description 34
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 63
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims abstract description 39
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims abstract description 39
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims abstract description 38
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims abstract description 38
- 210000004027 cell Anatomy 0.000 claims description 97
- 230000004083 survival effect Effects 0.000 claims description 25
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 24
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 23
- 229960005486 vaccine Drugs 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 229960002621 pembrolizumab Drugs 0.000 claims description 15
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 14
- 201000005202 lung cancer Diseases 0.000 claims description 14
- 208000020816 lung neoplasm Diseases 0.000 claims description 14
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 12
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 12
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 11
- 102000017578 LAG3 Human genes 0.000 claims description 11
- 229960003301 nivolumab Drugs 0.000 claims description 11
- 108010017987 CD30 Ligand Proteins 0.000 claims description 10
- 108010029697 CD40 Ligand Proteins 0.000 claims description 10
- 102100032937 CD40 ligand Human genes 0.000 claims description 10
- 102000018697 Membrane Proteins Human genes 0.000 claims description 10
- 108010052285 Membrane Proteins Proteins 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004473 OX40 Ligand Human genes 0.000 claims description 9
- 108010042215 OX40 Ligand Proteins 0.000 claims description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 9
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 102100036008 CD48 antigen Human genes 0.000 claims description 5
- 108010084313 CD58 Antigens Proteins 0.000 claims description 5
- 102100025221 CD70 antigen Human genes 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 5
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 5
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 5
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 5
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 5
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 5
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 5
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 5
- 108010041341 Integrin alpha1 Proteins 0.000 claims description 5
- 108010055795 Integrin alpha1beta1 Proteins 0.000 claims description 5
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 5
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 5
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims description 5
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 5
- 101150030213 Lag3 gene Proteins 0.000 claims description 5
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 5
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 5
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 5
- 101710165202 T-cell surface antigen CD2 Proteins 0.000 claims description 5
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 5
- 208000009956 adenocarcinoma Diseases 0.000 claims description 5
- 230000021164 cell adhesion Effects 0.000 claims description 5
- 229950009791 durvalumab Drugs 0.000 claims description 5
- 229940056913 eftilagimod alfa Drugs 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 229950010773 pidilizumab Drugs 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 229950007217 tremelimumab Drugs 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 4
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 239000013543 active substance Substances 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 238000002255 vaccination Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 102000004634 CD30 Ligand Human genes 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000002627 4-1BB Ligand Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100039328 Endoplasmin Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- -1 PD- 1 Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000230 acceptable toxicity Toxicity 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- INOZZBHURUDQQR-AJNGGQMLSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 INOZZBHURUDQQR-AJNGGQMLSA-N 0.000 description 1
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010040956 Ala-Asp-Glu-Leu Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100011744 Dictyostelium discoideum grp94 gene Proteins 0.000 description 1
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150007616 HSP90AB1 gene Proteins 0.000 description 1
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 description 1
- 101000812663 Homo sapiens Endoplasmin Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 101000812646 Mus musculus Endoplasmin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010022937 endoplasmin Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 108010041601 histidyl-aspartyl-glutamyl-leucine Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Definitions
- Cancer is a disease in which abnormal cells divide without proper control and are able to invade other tissues, spreading to other parts of the body through the blood and lymphatic systems.
- cancer remains one of the leading causes of morbidity and death in developed countries.
- treatments presently available for cancer including chemotherapy, radiation therapy, surgical intervention, and the use of various therapeutic agents including, for example, natural products, derivatives of natural products, and synthetic compounds.
- standard treatment of most aggressive tumors continues to be surgical resection, chemotherapy, and radiotherapy. While increasingly successful, each of these treatments still causes numerous undesired side effects.
- lung cancer is one of the leading causes of cancer-related mortality in the United States.
- the ACS estimated that there would be 224,210 new cases of lung cancer diagnosed in the United States alone in 2014, with almost 160,000 lung cancer-related deaths.
- the present application provides compositions and methods for the treatment of cancer. More particularly, the inventors have developed novel compositions containing a combination of active agents, and a method for treating cancer that includes administering the active agents in combination.
- this document is based at least in part on the development of treatments that include administering to a patient a composition containing multiple active agents.
- this document is based in part on the discovery that administration to a patient of a modified heat shock protein in combination with (a) one or more checkpoint inhibitors, (b) one or more T cell co- stimulators, or (c) one or more checkpoint inhibitors and one or more T cell co- stimulators leads to a surprising increase in the expansion of tumor specific CD8+ T cells, which, in turn, provides effective cancer treatment.
- compositions and methods provided herein may be very valuable in the treatment of cancer, as their use may provide greater efficacy and/or potency, resulting in improved therapeutic response, diminished side effects, or both, as compared to using traditional cancer therapeutics.
- this document features a method of treating a cancer in a human subject, where the method includes administering to the subject a therapeutically effective amount of a vaccine containing a plurality of host cells, each of the host cells co-expressing at least one tumor antigen and a heat shock protein modified to be secreted from each of the host cells, and a composition containing one or more T-cell co- stimulators.
- this document features a method of treating a cancer in a human subject, where the method includes administering to the subject a therapeutically effective amount of (a) a vaccine containing a plurality of host cells, each of the host cells co-expressing at least one tumor antigen and a heat shock protein modified to be secreted from each of the host cells, (b) a composition containing one or more checkpoint inhibitors, and (c) a composition containing one or more T-cell co- stimulators.
- the one or more T-cell co-stimulators can be selected from the group consisting of B7-1, B7-2, B7-h/B7rp- l, CD48, GITR, ICAM-1, ICAM-2, ICAM- 3, LFA-1, LFA-2, LFA-3, VLA-1, VCAM-1, CD30 Ligand (CD30L), CD40 Ligand (CD40L), 4- IBB Ligand (4-1BBL), OX40 ligand, CD70, CD24, LIGHT, and other cell adhesion proteins and other cell surface proteins that can activate T cell co-stimulatory pathways through T cell surface proteins.
- the one or more T-cell co-stimulators can be OX40 ligand, or can be 4- IBB Ligand.
- the one or more checkpoint inhibitors can be selected from the group consisting of CTLA-4, PD-1, PD-L1, LAG-3, IDO, TGF-beta, and TIM-3.
- this document features a composition containing a vaccine that contains a plurality of host cells, each of the host cells co-expressing at least one tumor antigen and a heat shock protein modified to be secreted from each of the host cells, and one or more checkpoint inhibitors.
- modified heat shock proteins are administered to a patient in combination with one or both of:
- modified hsps can be produced by various methods known in the art.
- the manipulations that result in their production can occur at the gene or protein level, but manipulations at the gene level can be particularly useful.
- the cloned coding region of an hsp can be modified by any of numerous recombinant DNA methods known in the art (see, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d ed., 1990, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and Ausubel et al, in Chapter 8 of Current Protocols in Molecular Biology. Greene Publishing Associates and Wiley Interscience, New York).
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des procédés, des trousses et des compositions destinés à traiter le cancer. Le traitement consiste à administrer à un patient nécessitant un tel traitement une combinaison formée d'une protéine de choc thermique modifiée et de : (a) un ou plusieurs inhibiteurs de point de contrôle; (b) un ou plusieurs co-stimulateurs des lymphocytes T; ou c) un ou plusieurs inhibiteurs de point de contrôle et un ou plusieurs co-stimulateurs des lymphocytes T.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946609P | 2014-02-28 | 2014-02-28 | |
| US61/946,609 | 2014-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015131176A1 true WO2015131176A1 (fr) | 2015-09-03 |
Family
ID=54009703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2015/018265 WO2015131176A1 (fr) | 2014-02-28 | 2015-03-02 | Compositions, procédés et trousses pour le traitement du cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2015131176A1 (fr) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016110593A1 (fr) * | 2015-01-09 | 2016-07-14 | Immutep S.A.S. | Préparations combinées pour le traitement d'un cancer ou d'une infection |
| US9644032B2 (en) | 2015-05-29 | 2017-05-09 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| EP3253876A4 (fr) * | 2015-02-06 | 2018-09-19 | Heat Biologics, Inc. | Vecteur co-exprimant un vaccin et des molécules co-stimulantes |
| US10736940B2 (en) | 2013-12-19 | 2020-08-11 | Immutep S.A.S. | Combined preparations for the treatment of cancer |
| US10844119B2 (en) | 2016-10-11 | 2020-11-24 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
| US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
| US11648223B2 (en) * | 2016-06-10 | 2023-05-16 | Io Therapeutics, Inc. | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy |
| US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100297154A1 (en) * | 1998-07-02 | 2010-11-25 | Genitrix, Llc | CD40 ligand-enhanced cells and methods of modulating an immune response to an antigen |
| US20120034242A1 (en) * | 2003-04-02 | 2012-02-09 | Biosante Pharmaceuticals, Inc. | Cytokine-expressing cellular vaccine combinations |
| US20130045202A1 (en) * | 2008-12-09 | 2013-02-21 | Genentech, Inc. | Anti-pd-l1 antibodies and articles of manufacture |
| US20130302376A1 (en) * | 2008-03-03 | 2013-11-14 | Nozomi Yamazaki | Allogeneic Cancer Cell-based Immunotherapy |
-
2015
- 2015-03-02 WO PCT/US2015/018265 patent/WO2015131176A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100297154A1 (en) * | 1998-07-02 | 2010-11-25 | Genitrix, Llc | CD40 ligand-enhanced cells and methods of modulating an immune response to an antigen |
| US20120034242A1 (en) * | 2003-04-02 | 2012-02-09 | Biosante Pharmaceuticals, Inc. | Cytokine-expressing cellular vaccine combinations |
| US20130302376A1 (en) * | 2008-03-03 | 2013-11-14 | Nozomi Yamazaki | Allogeneic Cancer Cell-based Immunotherapy |
| US20130045202A1 (en) * | 2008-12-09 | 2013-02-21 | Genentech, Inc. | Anti-pd-l1 antibodies and articles of manufacture |
Non-Patent Citations (1)
| Title |
|---|
| CAPECE ET AL.: "Targeting Costimulatory Molecules to Improve Antitumor Immunity", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 179, no. 11, 2012, pages 7365 - 17, XP055159186, ISSN: 1110-7243 * |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10736940B2 (en) | 2013-12-19 | 2020-08-11 | Immutep S.A.S. | Combined preparations for the treatment of cancer |
| US10874713B2 (en) | 2015-01-09 | 2020-12-29 | Immutep S.A.S. | Combined preparations for the treatment of cancer or infection |
| US10940181B2 (en) | 2015-01-09 | 2021-03-09 | Immutep S.A.S. | Combined preparations for the treatment of cancer or infection |
| US11684654B2 (en) | 2015-01-09 | 2023-06-27 | Immutep S.A.S. | Combined preparations for the treatment of cancer or infection |
| WO2016110593A1 (fr) * | 2015-01-09 | 2016-07-14 | Immutep S.A.S. | Préparations combinées pour le traitement d'un cancer ou d'une infection |
| US10758611B2 (en) | 2015-02-06 | 2020-09-01 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| US10780161B2 (en) | 2015-02-06 | 2020-09-22 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| AU2016215175B2 (en) * | 2015-02-06 | 2021-09-16 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| EP3253876A4 (fr) * | 2015-02-06 | 2018-09-19 | Heat Biologics, Inc. | Vecteur co-exprimant un vaccin et des molécules co-stimulantes |
| US10683357B2 (en) | 2015-05-29 | 2020-06-16 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| US9644032B2 (en) | 2015-05-29 | 2017-05-09 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| US11466092B2 (en) | 2015-05-29 | 2022-10-11 | Bristol-Myers Squibb Company | Antibodies against OX-40 and uses thereof |
| US11648223B2 (en) * | 2016-06-10 | 2023-05-16 | Io Therapeutics, Inc. | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy |
| US10844119B2 (en) | 2016-10-11 | 2020-11-24 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
| US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
| US10882908B2 (en) | 2016-10-11 | 2021-01-05 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
| US11993651B2 (en) | 2016-10-11 | 2024-05-28 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Showalter et al. | Cytokines in immunogenic cell death: applications for cancer immunotherapy | |
| WO2015131176A1 (fr) | Compositions, procédés et trousses pour le traitement du cancer | |
| JP6457940B2 (ja) | 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法 | |
| JP6858558B2 (ja) | 新生物疾患の処置、減少、阻害、又は制御において使用するための、免疫調節薬 | |
| US20130071403A1 (en) | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy | |
| JP2019203035A (ja) | がんの治療のための組合せ調製物 | |
| Weide et al. | Intralesional treatment of metastatic melanoma: a review of therapeutic options | |
| Marelli et al. | A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer | |
| US20170072038A1 (en) | Combination therapy with wt1 peptide vaccine and temozolomide | |
| JP2024507283A (ja) | 抗腫瘍薬を調製するための免疫療法薬と併用でのｐｐａｒ－デルタ阻害剤の使用 | |
| Melssen et al. | Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer | |
| US20190241660A1 (en) | Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer | |
| US20230256066A1 (en) | Pharmaceutical composition for use in the treatment of cancer | |
| WO2020114098A1 (fr) | Application de polyphénol de thé dans un inhibiteur de points de contrôle immunitaires et dans la préparation de médicaments antitumoraux | |
| Li et al. | Tumor-targeted chemoimmunotherapy with immune-checkpoint blockade for enhanced anti-melanoma efficacy | |
| US11696936B2 (en) | Treatment of cancer | |
| US20200237860A1 (en) | Hsp70 based combination therapy | |
| CN110740747A (zh) | Nk-92细胞和il-15激动剂联合治疗 | |
| Yang | mRNA vaccines in cancer immunotherapy: clinical benefits, limitations, and future | |
| CN102935228A (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| Zheng et al. | Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors | |
| CN116585315A (zh) | 用于调节pd-1信号转导的组合物 | |
| Kothari et al. | Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects | |
| WO2023141229A2 (fr) | Régimes viraux oncolytiques pour le traitement du cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15756024 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15756024 Country of ref document: EP Kind code of ref document: A1 |